Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL

This study looks at whether using blinatumomab — an antibody that directs immune cells to attack leukemia cells — as a short bridge therapy before a stem cell transplant from a donor improves outcomes in patients with B-cell acute lymphoblastic leukemia (B-ALL) who have a low amount of remaining cancer. **You may be eligible if...** - You have been diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) - You are 16 years or older - You have records of your disease status both before and after the transplant **You may NOT be eligible if...** - You received blinatumomab for more than 14 days - Your leukemia burden was 10% or higher before starting treatment - You had severe organ dysfunction (heart failure, liver failure, kidney failure) before treatment - You had leukemia in your central nervous system (brain or spinal fluid) Talk to your doctor to see if this trial is right for you.